Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties | Biosimilars Advisory Service | US/EU | 2014
The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development…
Umeclidinium Bromide Vilanterol (Anoro Ellipta) (COPD) (Wave 1) | LaunchTrends | US | 2014
This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (…
Population Health Management in Type 2 Diabetes: What Does This Approach Mean for Specific Diabetes Brands? | Physician & Payer Forum | US | 2014
Population health management (PHM) represents one of the long-term goals of the healthcare industry: building upon the patient-centered medical home concept to provide proactive support to a…
COPD (Positioning of Current and Emerging Agents) | Physician & Payer Forum | Brazil and Mexico | 2014
Improvements in patient access to novel treatments for chronic obstructive pulmonary disease (COPD) in Brazil and Mexico are largely dependent on the expansion of drug coverage by local authorities…
Autoimmune Diseases ( High-Cost Biologics for Autoimmune Diseases: How Will Healthcare Reform and Payer-Led Cost-Taming Strategies Impact Brand Prescribing? ) | Physician & Payer Forum | US | 2014
As the pharmaceutical pipeline begins to churn out specialty products at a higher rate than traditional therapies, the nation’s healthcare payers are experiencing double-digit growth in their…
